drugset / Trial / NCT04913103
Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL
NaSingle-groupOpen-labelTreatment
Summary
A Czech Lymphoma Study Group, phase II, open-label, study of polatuzumab-vedotin in combination with bendamustine and rituximab for patients with mantle cell lymphoma, who relapse after previous therapy with Bruton tyrosine kinase inhibitor
Timeline
- Start
- 2021-09-01
- Primary completion
- 2026-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | — | Intravenous |
| Subject | Polatuzumab Vedotin | Other / unclassified | — | Intravenous |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |